aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...
aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ... aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...
saerTaSoriso saxeli stavudini (d4T) tenofoviri (TDF) triple nuceozidi (TRZ) zidovudini (ZDV or AZT) nnrti delavirdini (DLV) efavirenzi (EFV) nevirapini (NVP) mwarmoeblis saxeli zeriti, zeriti XR staveqsi sraveqsi-L (lamivudini/stavudini) sraveqsi-LN (lamivudini/nevirapini/stavudini) staviri lamiviri-S (lamivudini/stavudini) triomuni (lamivudini/nevirapini/stavudini) lamistari (lamivudini/stavudini) nevilasti (lamivudini/nevirapini/stavudini) stagi staviri avostavi triviro-LNS (lamivudini/nevirapini/stavudini) virolansi (lamivudini/nevirapini/stavudini) virolisi, koviro (lamivudini/stavudini) virostavi truvada (tenofoviri/emtricitabini) vireadi (tenofoviri) atripla (efavirenzi/emtricitabini/tenofoviri) triziviri United Kingdom, United States (zidovudini/lamivudini/abakaviri) kombiviri United Kingdom, United States (lamivudini /zidovudini) retroviri United Kingdom, United States triziviri United Kingdom, United States (zidovudini/lamivudini/abakaviri) zidoveqsi zidoviri duoviri (lamivudini /zidovudini) zido-H (zidovudini) antiviri aviro-Z virokombi (lamivudini /zidovudini) viroli LZ (abakaviri/lamivudini/zidovudini) viro-Z reskriptori Sustiva Europe, United Kingdom, Stocrin Australia, Europe, Latin America, South Africa atripla (efavirenzi/emtricitabini/tenofoviri) viranzi efaviri estiva efferveni viramuni nevireqsi staveqsi LN (lamivudini/nevirapini/stavudini) duoviri-N (lamivudini/nevirapini/zidovudini) nevimuni triomuni (lamivudini/nevirapini/stavudini) nevilasti (lamivudini/nevirapini/stavudini) gpoviri farmaceptuli kompania Bristol-Myers Squibb Aurobindo Cipla Genixpharma GPO (Thailand) Ranbaxy Gilead Sciences Bristol-Myers Squibb GlaxoSmithKline GlaxoSmithKline Aurobindo Cipla Genixpharma GPO (Thailand) Ranbaxy Pfizer, Inc. Bristol-Myers Squibb Aurobindo Cipla Genixpharma Ranbaxy Boehringer Ingelheim Aurobindo Cipla Genixpharma GPO (Thailand) 64
saerTaSoriso saxeli mwarmoeblis saxeli farmaceptuli kompania nevipani triviro LNS (lamivudini/nevirapini/stavudini) Ranbaxy virolansi (lamivudini/nevirapini/stavudini) zidoveqsi-LN (lamivudini/nevirapini/zidovudini) Fusion Inhibitors enfuvirtidi, T-20 fuzeoni Roche Pharmaceuticals & Trimeris, Inc. proteazas inhibitorebi amprenaviri (APV) Agenerase United Kingdom, United States GlaxoSmithKline atazanaviri (ATV) Reyataz Europa, US, Zrevada Bristol-Myers Squibb fosamprenaviri (FPV) leqsiva US, telziri United Kingdom GlaxoSmithKline and Vertex Indiraviri (IDV) kriqsivani Merck & Co. indiveqsi Aurobinda indiviri Cipla indiviri Genixpharma virodini Ranbaxy lopinaviri/ritonaviri kaletra Abbott Laboratories kombinacia (LPV/r) nelfinaviri (NFV) viracepti Pfizer, Inc., Roche Pharmaceuticals nelveqsi Aurobinda nelviri Cipla nelfini Genixpharma nefaviri Ranbaxy ritonaviri (RTV) norviri Abbott Laboratories ritoviri Hetero/Genix seqvinaviri (SQV) damateba 7. leqsikoni Fortovase europe, United Kingdom, United States Invirase United Kingdom, United States 65 Roche Pharmaceuticals mkurnalobis reJimis dacva. rodesac wamlis dozis 95%-ia miRebuli saubaria mkurnalobisadmi damyolobaze. am maCveneblis qvemoT saubaria mkurnalobis reJimis darRvevaze. foni bazisuri nawilia arT mkurnalobisa, romelic Cveulebriv Seicavs or nrti-s, romelic Tavis mxriv fonia proteazas inhibitoris an pi-s da SeWris inhibitorisTvis. termini “optimaluri foni” gulisxmobs problemis regulirebas nrti-sTvis, romelic damyarebulia rezistentobis testis Sedegze. medegianoba aris mkurnalobis reJimis dacvis Zveli termini. genetikuri barieri gamoxatavs virusis mutaciis im raodenobas, romelic saWiroa wamlebis mimarT rezistentobis ganviTarebisTvis. rezistentoba erTi mutaciiT niSnavs dabal genetikur bariers. rezistentoba aTi mutaciiT niSnavs Zalian maRal genetikur bariers, Tumca aseTi daxasiaTeba SeiZleba Seicvalos. maRali mutacia warmoadgens cvlilebebs virusis rnm-Si, romelic ganapirobebs rezistentobas arT-s wamlebze an mTlian klasze.
- Page 13 and 14: Sidsi registrirebulia msoflios 216
- Page 15 and 16: egistrirebul SemTxveevaTa 79% saqar
- Page 17 and 18: adamianis imunodeficitis virusis sa
- Page 19 and 20: aiv rnm-is koncentracia plazmaSi mk
- Page 21 and 22: SeuZlebelia da gadamwyveti misi dia
- Page 23 and 24: persistuli generalizebuli limfadeno
- Page 25 and 26: signalis amplifikacia komplementuri
- Page 27 and 28: • vizitamde rezistentobis testis
- Page 29 and 30: • adamianis papilomavirusi (maxvi
- Page 31 and 32: etinitis identifikaciisTvis, rodesa
- Page 33 and 34: cxrili 8 rekomendaciebi arT dawyebi
- Page 35 and 36: arv medikamentebi arseboben Semdegi
- Page 37 and 38: aCveneben, rom pirveladi rezistento
- Page 39 and 40: - tabletebis Cveneba pacientisTvis
- Page 41 and 42: - aqedan gamomdinare, nrti+anrti re
- Page 43 and 44: igulisxmeba im medikamentebis kombi
- Page 45 and 46: X (arv): testebi, romlebic unda Cat
- Page 47 and 48: maRali mgrZnobeloba abakaviri (ABC
- Page 49 and 50: transaminazebis elevacia anrti (all
- Page 51 and 52: ARV toqsiuroba menejmenti nefrotoqs
- Page 53 and 54: xSiri oportonistuli infeqciebia, ma
- Page 55 and 56: cxrilebis wakiTxvis magaliTi 1. cxr
- Page 57 and 58: damateba2. jandacvis msoflio organi
- Page 59 and 60: damateba 4. ZiriTadi informacia ant
- Page 62 and 63: damateba 5. mkurnalobis reJimis dac
- Page 66 and 67: mcire mutacia muSaobs kombinaciaSi.
- Page 68 and 69: 25. Phillips AN et al. Viral load o
- Page 70 and 71: Suppl 2:S171-176. 73. Altice FL, Mo
- Page 72 and 73: 122. Koval CE et al. Immune reconst
- Page 74 and 75: kandidozi dRe yovel dRe - ko-trimoq
- Page 76 and 77: karcinoma (ara SidsTan perikardiuli
- Page 78 and 79: o cxeleba o wonaSi kleba o Ramis of
- Page 80 and 81: indikatorebi filtvis darRveuli funq
- Page 82 and 83: o yvelaze xSirad viTardeba diarea,
- Page 84 and 85: o glukokortikoidebis sistematiuri m
- Page 86 and 87: 100 mg/dReSi meore rigis sqemebi am
- Page 88 and 89: o eqspoziciis Sedegad daavadebis ga
- Page 90 and 91: o remisiis miRweva Zalian Znelia da
- Page 92 and 93: qimioTerapiiT (mag : B-ALL reJimi)
- Page 94 and 95: • imunodeficitis mqone pacientebS
- Page 96 and 97: an famcikloviri 500 mg 3-jer dReSi
- Page 98 and 99: • berkitis-tipis limfoma; • naz
- Page 100 and 101: 3.2.2. cxeleba aiv inficirebulebSi
- Page 102 and 103: afTozuri wylulebi stomatiti qeiliti
- Page 104 and 105: ganmavlobaSi 2 Tvis manZilze (xelis
- Page 106 and 107: o gamonayari warmodgenilia mravlobi
- Page 108 and 109: 20. Chen XM et al. Cryptosporidiosi
- Page 110 and 111: Tavi IV. aiv infeqcia/SidsiT daavad
- Page 112 and 113: inficirebul bavSvebSi (ramdenadac a
saerTaSoriso saxeli mwarmoeblis saxeli farmaceptuli<br />
kompania<br />
nevipani<br />
triviro LNS (lamivudini/nevirapini/stavudini)<br />
Ranbaxy<br />
virolansi (lamivudini/nevirapini/stavudini)<br />
zidoveqsi-LN (lamivudini/nevirapini/zidovudini)<br />
Fusion Inhibitors<br />
enfuvirtidi, T-20 fuzeoni Roche<br />
Pharmaceuticals &<br />
Trimeris, Inc.<br />
proteazas inhibitorebi<br />
amprenaviri (APV) Agenerase United Kingdom, United States GlaxoSmithKline<br />
atazanaviri (ATV) Reyataz Europa, US, Zreva<strong>da</strong> Bristol-Myers Squibb<br />
fosamprenaviri (FPV) leqsiva US, telziri United Kingdom GlaxoSmithKline<br />
and Vertex<br />
Indiraviri (IDV)<br />
kriqsivani<br />
Merck & Co.<br />
indiveqsi<br />
Aurobin<strong>da</strong><br />
indiviri<br />
Cipla<br />
indiviri<br />
Genixpharma<br />
virodini<br />
Ranbaxy<br />
lopinaviri/ritonaviri kaletra<br />
Abbott Laboratories<br />
kombinacia (LPV/r)<br />
nelfinaviri (NFV) viracepti<br />
Pfizer, Inc., Roche<br />
Pharmaceuticals<br />
nelveqsi<br />
Aurobin<strong>da</strong><br />
nelviri<br />
Cipla<br />
nelfini<br />
Genixpharma<br />
nefaviri<br />
Ranbaxy<br />
ritonaviri (RTV) norviri<br />
Abbott Laboratories<br />
ritoviri<br />
Hetero/Genix<br />
seqvinaviri (SQV)<br />
<strong>da</strong>mateba 7. leqsikoni<br />
Fortovase europe, United Kingdom, United States<br />
Invirase United Kingdom, United States<br />
65<br />
Roche<br />
Pharmaceuticals<br />
mkurnalobis reJimis <strong>da</strong>cva. rodesac wamlis dozis 95%-ia miRebuli<br />
saubaria mkurnalobisadmi <strong>da</strong>myolobaze. am maCveneblis qvemoT<br />
saubaria mkurnalobis reJimis <strong>da</strong>rRvevaze.<br />
foni bazisuri nawilia arT mkurnalobisa, romelic Cveulebriv<br />
Seicavs or nrti-s, romelic Tavis mxriv fonia proteazas inhibitoris<br />
an pi-s <strong>da</strong> SeWris inhibitorisTvis. termini “optimaluri foni”<br />
gulisxmobs problemis regulirebas nrti-sTvis, romelic<br />
<strong>da</strong>myarebulia rezistentobis testis Sedegze.<br />
medegianoba aris mkurnalobis reJimis <strong>da</strong>cvis Zveli termini.<br />
genetikuri barieri gamoxatavs virusis mutaciis im raodenobas,<br />
romelic saWiroa wamlebis mimarT rezistentobis ganviTarebisTvis.<br />
rezistentoba erTi mutaciiT niSnavs <strong>da</strong>bal genetikur bariers.<br />
rezistentoba aTi mutaciiT niSnavs Zalian maRal genetikur bariers,<br />
Tumca aseTi <strong>da</strong>xasiaTeba SeiZleba Seicvalos.<br />
maRali mutacia warmoadgens cvlilebebs virusis rnm-Si, romelic<br />
ganapirobebs rezistentobas arT-s wamlebze an mTlian klasze.
Change language